1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. BeiGene, Ltd.
  6. News
  7. Summary
    BGNE   US07725L1026

BEIGENE, LTD.

(BGNE)
  Report
Real-time Estimate Cboe BZX  -  01:57 2022-08-09 pm EDT
194.48 USD   -3.84%
11:48aJPMorgan Assumes BeiGene at Overweight with $296 Price Target
MT
10:28aNovartis-BeiGene Liver Cancer Drug Works As Well As Bayer's Nexavar in Phase 3 Study
MT
06:02aBeiGene Announces Positive Global Phase 3 Trial Results for PD-1 Inhibitor Tislelizumab in First-Line Unresectable Hepatocellular Cancer
BU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

BeiGene Says Esophageal Cancer Combination Therapy Improved Overall Survival in Phase 3 Trial

06/30/2022 | 05:52am EDT


© MT Newswires 2022
All news about BEIGENE, LTD.
11:48aJPMorgan Assumes BeiGene at Overweight with $296 Price Target
MT
10:28aNovartis-BeiGene Liver Cancer Drug Works As Well As Bayer's Nexavar in Phase 3 Study
MT
06:02aBeiGene Announces Positive Global Phase 3 Trial Results for PD-1 Inhibitor Tislelizumab..
BU
08/08BEIGENE, LTD. Management's Discussion and Analysis of Financial Condition and Results ..
AQ
08/08Nomura Adjusts BeiGene's Price Target to $286.31 From $277.35, Maintains Buy Rating
MT
08/08Nomura Adjusts Beigene's Price Target to HK$172.89 From HK$167.48, Keeps at Buy
MT
08/05WALL STREET STOCK EXCHANGE : Another case of good news is bad news
MS
08/05ANALYST RECOMMENDATIONS : Eli Lilly, KLA, Kellogg, Epam Systems, BeiGene...
MS
08/05BeiGene Shares Gain After Doubling of Second-Quarter Revenue
DJ
08/04BeiGene Q2 Net Loss per ADS Widens as Revenue Rises; Shares Surge
MT
More news
Analyst Recommendations on BEIGENE, LTD.
More recommendations
Financials (USD)
Sales 2022 1 394 M - -
Net income 2022 -1 619 M - -
Net cash 2022 2 960 M - -
P/E ratio 2022 -16,6x
Yield 2022 -
Capitalization 20 926 M 20 926 M -
EV / Sales 2022 12,9x
EV / Sales 2023 9,06x
Nbr of Employees 8 500
Free-Float 99,0%
Chart BEIGENE, LTD.
Duration : Period :
BeiGene, Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BEIGENE, LTD.
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 16
Last Close Price 202,24 $
Average target price 275,30 $
Spread / Average Target 36,1%
EPS Revisions
Managers and Directors
John V. Oyler Director
Xiao Bin Wu President & Chief Operating Officer
Julia Wang Chief Financial & Accounting Officer
Lai Wang Global Head-Research & Development
Christiane Langer Senior Vice President-Global Medical Affairs
Sector and Competitors
1st jan.Capi. (M$)
BEIGENE, LTD.-25.35%20 926
GILEAD SCIENCES, INC.-15.87%77 266
VERTEX PHARMACEUTICALS31.16%75 386
REGENERON PHARMACEUTICALS, INC.-2.84%67 420
BIONTECH SE-28.97%41 143
WUXI APPTEC CO., LTD.-20.64%40 375